ALL WEBINARS

News about a not-too-distant future of personal genomics is coming at us hard and fast. For example, the New York Times reported on June 1 that the complete DNA sequence of Nobel laureate James C. Watson, of DNA double-helix fame, has been sequenced and ...

Searching for the wherewithal to push on with your work on a promising new Alzheimer therapy? The NIH offers funding for research support at every step of the process, from early drug discovery right through to phase 3 clinical trials, if you know where ...

These are comfortable times for the amyloid hypothesis, it would seem. Every week brings more good news about some anti-amyloid intervention having “cured” mice from their “Alzheimer’s.” On the human front, we are eagerly awaiting such therapeutics to ...

There is now a concerted push in the research community to find pharmacological and/or non-pharmacological interventions that can prevent or slow the progression of Alzheimer disease. But prevention trials promise to be long and potentially costly affairs ...

At first blush, Alzheimer disease and fragile X syndrome may appear as chalk and cheese, since the former is a neurodegenerative disease and the latter a developmental disorder. However, both are characterized by synaptic pathology and as exemplified by a ...

The amyloid-β-yielding extracellular domain of APP has gotten most of the attention over the last decade or so, but inside the cell there is a large cytoplasmic fragment that might be the key to understanding the true nature of APP. Sanjay Pimplikar ...

Debra Revere discussed how the tools developed by the Telemakus Research Group have been used to extract research methods, animal models, data from tables and figures, and research results from published literature. View Presentation You will need ...

Katrina Gwinn-Hardy led this Web seminar and discussion on the whole genome study of Parkinson disease which was published recently in Lancet Neurology. Co-author Gwinn-Hardy presented the findings and introduced some discussion topics around data sharing ...

Despite the availability of a wide range of animal models of Alzheimer disease, none of them are able to fully recapitulate all the facets of the disease. Axonopathy is a case in point. Although there has been renewed interest in the link between axonal ...

We invite you to participate in this "offline" Forum discussion led by Vincent Marchesi of Yale University. Coming from a different research field, Marchesi has in recent years followed the AD literature as closely as have few other outside ...

Gordon Shepherd and Kei Cheung from Yale University led this Web seminar. Our featured presenters provided an introduction to SenseLab, which is a long-standing database project to build integrated multidisciplinary models of neurons and neural systems. ...

Ben Wolozin of the Boston University School of Medicine presented some results from analyzing a 4.5 million-subject database of medical records to identify medications that are associated with reduction or increase in the incidence of dementia. His team& ...

Dr. Coleman led this live discussion on how biomarker information and basic science of AD can inform each other. He reviewed how the more common biomarkers of tau and Aß peptides relate to the major neurobiological deficits in AD—synaptic loss and ...